Intercept Plasma System: Phase III

Interim data from the first 9 patients with congenital blood clotting deficiencies in CERS's 34-patient Phase IIIa trial showed that Intercept-treated

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE